iRhythm Zio Cardiac Monitoring Service

iRhythm Technologies, Inc. is a digital health care company focused on detecting, predicting and preventing disease, and its October 2026 press release was datelined San Francisco. It pairs Zio wearable biosensors with cloud-based analytics and proprietary algorithms that turn heartbeat data into clinical information.

The Zio ECG monitor and Zio AT are worn on the chest, and the iRhythm Service combines an FDA-cleared deep-learned algorithm with reports verified by qualified cardiac technicians. Providers use the ZioSuite portal and EHR integration to interpret reports and manage patients, while patients log symptoms in the MyZio app. In October 2026 iRhythm completed the acquisition of VitalConnect to add mobile cardiac telemetry and multi-vitals monitoring.

• Zio wearable: ECG monitor and Zio AT designed for comfort and easy wear.
• Deep-learned algorithm: FDA-cleared algorithm with reports verified by qualified cardiac technicians.
• ZioSuite portal: providers interpret reports and manage patients, including on mobile.
• EHR integration: supports data entry and clinic workflow.
• MyZio app: symptom logging, education and reminders for patients.
• VitalConnect platform: mobile cardiac telemetry for up to 30 days and up to 11 physiological parameters.

Cardiology departments replacing Holter with multi-day patch monitoring for palpitations and syncope. Primary care networks referring patients for arrhythmia screening with centralized report review. Hospitals planning post-discharge cardiac telemetry for patients at risk.

The company reports over 12 million patients analyzed and over 2 billion hours of curated heartbeat data. It cites 99% physician agreement with end-of-wear reports based on a 2023 internal review. Technician-verified reports and EHR integration reduce interpretation workload for clinics. Wearable design supports patient compliance, though no figure is given.

Ambulatory ECG is shifting from short Holter recordings to multi-day patches with algorithm-assisted reading, and vendors are widening into mobile cardiac telemetry and hospital-to-home care. Regulatory marks in the UK, Europe and Japan show the model is being exported to Asian markets; Vietnamese hospitals could use the same service model to handle arrhythmia workups with limited cardiology staff.

Holds FDA 510(k) clearance, CE mark, UKCA mark and PMDA approval, with regional sites for the US, UK, Japan and Europe. VitalConnect was acquired for about USD 237.5 million in cash plus shares. The AVALON study was published in 2025. Founding year not stated.